MustGrow Biologics Corp. announced on September 23, 2024, that it has successfully transitioned from research and development to commercialization. The manufacturing and sales of its TerraSante biofertility product have commenced, with an anticipated increase in sales volume in 2025 and 2026. Additionally, the commercialization of its TerraMG soil biopesticide under the Bayer commercial agreement in the EU, Middle East, and Africa is progressing. Registration work for the TerraMG soil biopesticide is ongoing in the U.S. and Canada.
Exclusive non-commercial agreements with NexusBioAg, Janssen PMP, and Sumitomo Corporation have expired, allowing MustGrow to explore commercial opportunities with multiple parties. The company’s intellectual property portfolio has grown to include 112 issued and pending patents. Management is set to deliver a presentation and Q&A session on September 24, 2024.
MustGrow is actively working towards commercializing its TerraSante and TerraMG products, validating product efficacy through sales, and expanding globally. The company is focused on increasing sales, margins, and return on investment in the future. MustGrow’s forward-looking statements highlight its plans for commercialization, state-level registrations, and product functionalities.
It is important to note that this press release contains forward-looking statements that involve risks and uncertainties. Readers are advised to refer to MustGrow’s continuous disclosure documents for more detailed information about the company. The release does not constitute an offer for the sale of securities in the United States, and approval from regulatory authorities is pending. The rights to this press release are reserved by MustGrow Biologics Corp. Source information can be accessed at the link provided.
